A case of sclerodermatous graft-versus-host disease responsive to imatinib therapy

Pediatric Dermatology

Volumn 28, Issue 2, 2011, Pages 172-175

  Lazar, Jozef ^a   Poonawalla, Tasneem ^a   Teng, Joyce M C ^a,b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b Dermatology and Pediatrics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIPOTRIOL; CLOBETASOL; CYCLOSPORIN; CYTOKINE; ETRETIN; IMATINIB; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PREDNISONE; PROTEIN TYROSINE KINASE; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA; UREA;

ADOLESCENT; ARTICLE; BRONCHIOLITIS OBLITERANS; CASE REPORT; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERPIGMENTATION; IMMUNOSUPPRESSIVE TREATMENT; NODULAR SCLEROSIS HODGKIN LYMPHOMA; PATHOGENESIS; PRIORITY JOURNAL; SCLERODERMATOUS GRAFT VERSUS HOST DISEASE; T LYMPHOCYTE;

ADOLESCENT; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SCLERODERMA, SYSTEMIC;

EID: 79954997848     PISSN: 07368046     EISSN: 15251470     Source Type: Journal    
DOI: 10.1111/j.1525-1470.2010.01301.x     Document Type: Article

References (15)

1. Socie G, Salooja N, Cohen A, et al., Nonmalignant late effects after allogeneic stem cell transplantation. Blood 2003; 101: 3373-3385. (Pubitemid 36857917)
2. Skert C, Patriarca F, Sperotto A, et al., Sclerodermatous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: incidence, predictors and outcome. Haematologica 2006; 91: 258-261.
3. White JM, Creamer D, du Vivier AW, et al., Sclerodermatous graft-versus-host disease: clinical spectrum and therapeutic challenges. Br J Dermatol 2007; 156: 1032-1038. (Pubitemid 46642860)
4. Moreno-Romero JA, Fernandez-Aviles F, Carreras E, et al., Imatinib as a potential treatment for sclerodermatous chronic graft-vs-host disease. Arch Dermatol 2008; 144: 1106-1109.
5. Svegliati S, Olivieri A, Campelli N, et al., Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood 2007; 110: 237-241. (Pubitemid 47026840)
6. Baroni SS, Santillo M, Bevilacqua F, et al., Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006; 354: 2667-2676.
7. Verrecchia F, Mauviel A, Farge D,. Transforming growth factor-beta signaling through the Smad proteins: role in systemic sclerosis. Autoimmun Rev 2006; 5: 563-569. (Pubitemid 44488757)
8. Bibi Y, Gottlieb AB,. A potential role for imatinib and other small molecule tyrosine kinase inhibitors in the treatment of systemic and localized sclerosis. J Am Acad Dermatol 2008; 59: 654-658.
9. Chandran S, Petersen J, Jacobs C, et al., Imatinib in the treatment of nephrogenic systemic fibrosis. Am J Kidney Dis 2009; 53: 129-132.
10. Buchdunger E, Cioffi CL, Law N, et al., Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295: 139-145.
11. Pannu J, Asano Y, Nakerakanti S, et al., Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate. Arthritis Rheum 2008; 58: 2528-2537.
12. Distler JH, Jungel A, Huber LC, et al., Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007; 56: 311-322. (Pubitemid 46106205)
13. Druker BJ, Talpaz M, Resta DJ, et al., Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1037. (Pubitemid 32267972)
14. Savage DG, Antman KH,. Imatinib mesylate-a new oral targeted therapy. N Engl J Med 2002; 346: 683-693. (Pubitemid 34815874)
15. Kerkela R, Grazette L, Yacobi R, et al., Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006; 12: 908-916. (Pubitemid 44175142)